We spoke with select PAH experts—
including authors of the ESC/ERS Guidelines—to better understand their views on a variety of topics in PAH. They discussed the importance of regular and robust risk assessment, the benefits of treatment escalation with risk escalation, the appropriate time to begin triple-combination therapy, and how to set patients up for success with UPTRAVI.

to better understand their views on a variety of topics in PAH. They discussed the importance of regular and robust risk assessment, the benefits of treatment escalation with risk escalation, the appropriate time to begin triple-combination therapy, and how to set patients up for success with UPTRAVI.

Healthcare professionals should consult the product label in their respective countries for full details of the indication, warnings and precautions, and safety information for UPTRAVI.

Video Series Overview